Viatris
OVERALL |
|
Owned |
USA |
Rating |
![]() |
Pharmaceuticals
Created in 2020 when Mylan merged with Pfizer's off-patent drug business, Upjohn.
Viatris Inc | USA | website |
Company Assessment
PRAISE | CRITICISM | INFORMATION | ||
Viatris Inc | ||||
This company received an S&P Global ESG Score of 27/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 7 Feb 2021). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2021) |
This company has corporate social responsibility claims on its website.
Source: company website (2021)
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
Source: company website (2020)
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
Source: Open Secrets (2021) |
Company Details
Type | Public company |
Founded | 2020 |
Revenue | US$20 billion in 2020 |
Subsidiaries | Mylan NV ![]() Pharmaceuticals One the world's largest manufacturers of prescription generic drugs. Merged with Upjohn in 2020 to create Viatris Inc. - Alphapharm Pty Ltd ![]() Pharmaceuticals Established in 1982. Makers of generic medicines. Alphapharm is the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme. Operates a manufacturing plant in Queensland. Acquired by Mylan in 2007 who merged with Upjohn in 2020 to form Viatris. Bought Aspen's portfolio of prescription and over-the-counter products in Australia for $188 million in 2019. - Meda AB ![]() Pharmaceutical manufacturer and marketer Products are prescription and OTC (over the counter) drugs. Main focus is on sales and marketing and as they do not develop early stage new products, new product growth is by acquisition. Products are sold in more than 150 countries, with own sales companies in 60 countries. Product areas are respiratory, dermatological and pain/inflammation. Acquired by Mylan in 2016. |
Contact Details
Address | Delaware, USA |
Website | www.viatris.com |
Products / Brands
Viatris Australia
Dermeze Skin Care
Dermeze Body Wash Dymadon Pain Relief Tablets Gastro-Stop Digestive Care Irish Moss Cold & Flu Stingose Antiseptic Tums Digestive Care Waxsol Eye & Ear Care Zantac Digestive Care |